Assessment of NFKBIE mutations in 1460 patients diagnosed with different lymphoid malignancies. (A) NFKBIE mutation frequency per disease entity. (B) OS in 143 PMBL patients according to NFKBIE mutation status (P value refers to log-rank test). (C) Recurrently mutated genes in PMBL. Based on WES generated on 7 PMBL cases from this series and available exome data on 7 cases from Mareschal et al.¹⁰  and Gunawardana et al.¹⁸  (D) Differentially expressed genes in NFKBIE wild-type (n = 21) vs deleted (n = 8) PMBL cases based on the NanoString PanCancer Pathways Panel plus an additional 30 genes (detailed in supplemental Methods). FL, follicular lymphoma; HL, Hodgkin lymphoma; MCL, mantle cell lymphoma; PCNSL, primary central nervous system lymphoma; SMZL, splenic marginal zone lymphoma; SLL, small lymphocytic lymphoma; T-ALL, T-cell acute lymphoblastic leukemia.